Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00583479 · ClinicalTrials.gov registry record · Phase 4

Prospective Study of Celiac Block Injection: 1 vs. 2

A Phase 4 study of Pancreatic Cancer and Chronic Pancreatitis, sponsored by Indiana University.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT00583479 is a Phase 4 study of Pancreatic Cancer and Chronic Pancreatitis that has completed, run by Indiana University. The registered enrollment target is 100 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00583479, a Phase 4 study of Pancreatic Cancer and Chronic Pancreatitis, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this prospective randomized study is to compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region.

Interventions

  • OTHER one injection into the celiac ganglion
  • OTHER two injections into the celiac ganglion

Study Locations (1)

Indiana

  • Clarian Health: Indiana University Hospital - Indianapolis

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2002-06
Est. Completion 2008-07
Phase Phase 4

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT00583479

The ClinicalTrials.gov registry entry for NCT00583479 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which one injection into the celiac ganglion is the first listed.

NCT00583479 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.

Frequently Asked Questions

What is clinical trial NCT00583479 about?

NCT00583479 is a clinical study titled "Prospective Study of Celiac Block Injection: 1 vs. 2". The purpose of this prospective randomized study is to compare the clinical effectiveness of EUS-guided CB performed with a single injection versus two injections of medication into the celiac ganglion region.

What is the current status of trial NCT00583479?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2002-06. Estimated completion is 2008-07.

What conditions does trial NCT00583479 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Chronic Pancreatitis.

What interventions are being tested in trial NCT00583479?

The interventions under investigation include: one injection into the celiac ganglion (OTHER), two injections into the celiac ganglion (OTHER).

Who is sponsoring clinical trial NCT00583479?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00583479 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.